Influence of Nutritional and Inflammational Status on Survival of Hemodialysis Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00410137
Verified December 2006 by Assaf-Harofeh Medical Center. Recruitment status was: Recruiting
prospective longitudinal measurements of nutritional status parameters (body composition by BIA, anthropometry and biochemical indexes), inflammatory response (CRP, inflammatory cytokines (IL-1, IL-6, IL-10),IGF-1, leptin and NOx blood levels) and morbidity and mortality data collection over 2 year period in patients receiving chronic hemodialysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female, age > 18 years, in chronic hemodialysis treatment at least 3 months
Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V > 1.2 and/or hemodialysis performed 4 hours 3 times weekly
Patients with normal hydration status (edema-free), with no neuro-muscular diseases
Informed consent obtained before any trial-related activities
Patients with edema, pleural effusion or ascites at their initial assessment
Patients with active malignant disease or liver cirrhosis
Patients with neuro-muscular diseases
Patients on chronic treatment with steroids on doses > 10 mg/day Prednisone (or equivalent)
Patients treated with immunosuppressive agents
Patients suffering from
Severe systemic infections
Heart failure (NYHA class III-IV)
The receipt of any investigational drug within 1 month prior to initiating of this study